Welcome to our dedicated page for Omada Health SEC filings (Ticker: OMDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Omada Health, Inc. (Nasdaq: OMDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a virtual-first, between-visit healthcare provider focused on cardiometabolic and musculoskeletal conditions, Omada uses these filings to report on its financial condition, operations, and material events related to its digital chronic care platform.
Investors can review current reports on Form 8-K, which Omada uses to furnish press releases announcing quarterly results and other significant developments. For example, recent 8-K filings reference earnings press releases for periods in which the company reported revenue, member growth, and updates on its GLP-1-related offerings and AI capabilities. These current reports help readers connect headline financial and operational metrics to the underlying SEC record.
In addition to 8-Ks, Omada’s periodic reports on Form 10-Q and Form 10-K (accessible through the SEC and linked from this page when available) typically contain more detailed information on revenue composition, cost structure, research and development spending, and risks associated with its virtual care and GLP-1 programs. These filings are particularly relevant for understanding how Omada’s cardiometabolic and musculoskeletal programs, GLP-1 Care Tracks, and prescribing and medication management capabilities are reflected in its financial statements and risk disclosures.
Stock Titan enhances this information with AI-powered summaries that explain key points from lengthy filings, helping readers quickly identify sections related to Omada’s chronic care model, GLP-1 initiatives, and digital health operations. Users can also monitor updates to OMDA’s filings in near real time, including new 8-Ks, 10-Qs, 10-Ks, and other relevant forms, to follow how the company reports on its performance and material events over time.
Omada Health, Inc. President Wei-Li Shao reported a sale of 8,866 shares of common stock on August 12, 2026 at $25.0167 per share in an open market or private transaction. The transaction was made pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026, and left the reporting person with 307,372 shares held directly.
Omada Health, Inc. Chief Financial Officer Steven L. Cook reported option exercises and related share sales in mid-August 2026. He exercised stock options covering 16,842 shares of common stock at exercise prices between $7.68 and $8.28 per share and sold the same total number of shares at weighted average prices around $25 per share. The transactions were made pursuant to a Rule 10b5-1 trading plan adopted on March 14, 2026, and include both fully vested options and options vesting monthly over four years.
Omada Health, Inc. insider Craig Gracey, Chief Accounting Officer, exercised stock options for 1,042 shares of common stock on August 10, 2026 at an exercise price of $6.57 per share. On the same date, 1,042 common shares were sold at $25.00 per share pursuant to a Rule 10b5-1 trading plan. Following the option exercise, 32,292 option shares remained outstanding and directly held.
OMDA disclosed a planned sale of restricted stock under Rule 144. Morgan Stanley Smith Barney LLC Executive Financial Services is listed for 8,866 common shares of OMDA with an approximate market value of $212,872.66, to be sold on or after August 12, 2026 on NASDAQ.
The shares trace to restricted stock units acquired from the issuer on June 1, 2026. Over the prior three months, a Rule 10b5-1 trading plan for Wei-Li Shao reported a sale of 4,037 common shares for proceeds of $69,600.71.
OMDA filed a Form 144 indicating a planned sale of common stock. The filing lists 2,715 common shares to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, related to an exercise of stock options on 08/11/2026 for cash. It also details prior Rule 10b5-1 sales by Steven Cook over the past three months, including sales such as 15,235 shares for $381,350.33 on 08/10/2026 and 23,263 shares for $529,500.01 on 07/01/2026, among other transactions of OMDA common stock on NASDAQ.
Omada Health, Inc. chief executive officer Sean P. Duffy exercised stock options covering a total of 21,570 shares of common stock at exercise prices of $8.28 and $9.18 on August 7 and 10, 2026, and sold 21,570 shares, including a weighted-average sale at $24.8075, pursuant to a 10b5-1 trading plan adopted on March 13, 2026. The filing also reports 851,659 shares of common stock held indirectly in family trusts for his family members, with beneficial ownership disclaimed except for his pecuniary interest.
OMDA reported a planned sale of 12,942 shares of common stock, to be acquired through an exercise of stock options for cash and routed through Morgan Stanley Smith Barney LLC Executive Financial Services. The planned transaction is dated August 10, 2026 with an indicated market value of $306,337.14. The filing also lists multiple prior Rule 10b5-1 sales for Sean Duffy between June 16 and August 7, 2026, each specifying the number of common shares sold and total proceeds.
OMDA shareholder Steven Cook filed a notice to sell OMDA common stock under Rule 144. The planned transaction involves 15,235 shares to be sold for cash on 08/10/2026 through Morgan Stanley Smith Barney LLC, following an Exercise of Stock Options on the same date.
The filing also lists recent Rule 10b5-1 sales of OMDA common stock by Steven Cook during June and July 2026, including multiple transactions ranging from a few hundred to tens of thousands of shares, with individual trade proceeds reaching over $650,000.
OMDA filed a notice that an affiliate intends to sell 1,042 shares of common stock, with Morgan Stanley Smith Barney LLC Executive Financial Services as broker, in a transaction noted for 08/10/2026. The shares are tied to an exercise of stock options, with payment in cash.
The filing also lists prior Rule 10b5-1 sales for Craig Gracey over the past three months, including trades on 06/12/2026, 06/22/2026, 06/24/2026, 06/26/2026, 06/29/2026, 06/30/2026, 07/01/2026, and 07/13/2026, each specifying common shares sold and total proceeds.
Omada Health, Inc. insider Sean Duffy filed a notice to sell common stock. The filing lists a planned sale of 8,628 common shares on 08/07/2026, to be issued through an exercise of stock options for cash. It also details multiple prior Rule 10b5-1 sales of common stock between June and August 2026, each with specified share amounts and aggregate proceeds.